Baseline cytogenetic/genetic features have been widely recognized to play a critical prognostic role in acute myeloid leukemia (AML) and have proven useful in designing riskadapted treatment strategies. Nevertheless, to improve further the outcome of AML patients we are still in need of accurate methods to explore the quality of response and to adequately discriminate patients who are likely to relapse over time from those who are in deep and stable remission. In this view, is it well established that measurement of leukemic cells surviving chemotherapy (called measurable residual disease, MRD) during the course of treatment may be a reliable biomarker in predicting relapse. Detection of MRD relies on highly sensitive techniques, such as quantitative polymerase chain reaction and multiparametric flow cytometry, which, due to their levels of specificity and sensitivity, are increasingly included in the decision-making process of AML treatment. In the present manuscript, we will review the current techniques of MRD investigation and their clinical contribution to AML management.

Palmieri, R., Buccisano, F., Maurillo, L., Del Principe, M.i., Paterno, G., Venditti, A., et al. (2020). Current strategies for detection and approach to measurable residual disease in Acute Myeloid Leukemia. MINERVA MEDICA, 111(5), 386-394 [10.23736/S0026-4806.20.07016-0].

Current strategies for detection and approach to measurable residual disease in Acute Myeloid Leukemia

Palmieri, Raffaele;Buccisano, Francesco;Del Principe, Maria Ilaria;Venditti, Adriano;
2020-01-01

Abstract

Baseline cytogenetic/genetic features have been widely recognized to play a critical prognostic role in acute myeloid leukemia (AML) and have proven useful in designing riskadapted treatment strategies. Nevertheless, to improve further the outcome of AML patients we are still in need of accurate methods to explore the quality of response and to adequately discriminate patients who are likely to relapse over time from those who are in deep and stable remission. In this view, is it well established that measurement of leukemic cells surviving chemotherapy (called measurable residual disease, MRD) during the course of treatment may be a reliable biomarker in predicting relapse. Detection of MRD relies on highly sensitive techniques, such as quantitative polymerase chain reaction and multiparametric flow cytometry, which, due to their levels of specificity and sensitivity, are increasingly included in the decision-making process of AML treatment. In the present manuscript, we will review the current techniques of MRD investigation and their clinical contribution to AML management.
2020
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
Palmieri, R., Buccisano, F., Maurillo, L., Del Principe, M.i., Paterno, G., Venditti, A., et al. (2020). Current strategies for detection and approach to measurable residual disease in Acute Myeloid Leukemia. MINERVA MEDICA, 111(5), 386-394 [10.23736/S0026-4806.20.07016-0].
Palmieri, R; Buccisano, F; Maurillo, L; Del Principe, Mi; Paterno, G; Venditti, A; Martinelli, G; Cerchione, C
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/254180
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact